medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2016, Number 3

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2016; 14 (3)

Oral Anticoagulants and their Involvement in Dermatologic Surgery

Guerra VÁE, Marfil RLJ, Ocampo CJ

Language: Spanish
References: 27
Page: 222-227
PDF size: 125.27 Kb.


ABSTRACT

Between 25 and 38% of patients who undergo a skin procedure used antithrombotic agents, so the dermatologist should know well the pharmacodynamics and pharmacokinetics, their indications and possible adverse effects. The decision to continue or discontinue treatment with oral anticoagulants is the risk of bleeding against the risk of a thrombotic event causing discontinuation. In this article we review aspirin and oral anticoagulants and its implications in cutaneous surgery.


REFERENCES

  1. Callahan S, Goldsberry A, Kim G, Yoo S. The management of antithrombotic medication in skin surgery. Dermatol Surg 2012; 38: 1417-26.

  2. Dixon AJ, Dixon MP, Dixon JB. Bleeding complications in skin cancer surgery are associated with warfarin but not aspirin therapy. Br J Surg 2007; 94: 1356-60.

  3. Otley CC. Continuation of medically necessary aspirin and warfarin during cutaneous surgery. Mayo Clin Proc 2003; 78: 1392-6.

  4. Kovich O, Otley CC. Thrombotic complications related to discontinuation of warfarin and aspirin therapy perioperatively for cutaneous operation. J Am Acad Dermatol 2003; 48: 233-7.

  5. Pirmohamed M. Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol 2006; 62(5): 509-11.

  6. Ansell J, Hirsh J, Poller L et al. The pharmacology and management of the vitamin K antagonists: the Seventh accp Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 204-33.

  7. García D, Ageno W, Bussey H et al. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 1: prevention. Am J Hematol 2009; 84: 579-83.

  8. Lewis KG, Dufresne RG. A meta-analysis of complications attributed to anticoagulation among patients following cutaneous surgery. Dermatol Surg 2008; 34: 160-4.

  9. Child N, Anjum N, Keohane SG, Cooper HL. A guide to anticoagulation and endocarditis prophylaxis during cutaneous surgery. Clin Exp Dermatol 2010; 35(8): 817-22.

  10. Juurlink DN. Drug interactions with warfarin: what clinicians need to know. cmaj 2007; 177(4): 369-71.

  11. Syed S, Adams BB, Liao W et al. A prospective assessment of bleeding and international normalized ratio in warfarin-anticoagulated patients having cutaneous surgery. J Am Acad Dermatol 2004; 51: 955-7.

  12. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.

  13. Gonsalves WI, Pruthi RK, Patnaik MM. The new oral anticoagulants in clinical practice. Mayo Clin Proc 2013; 88(5): 495-511.

  14. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. Engl J Med 2009; 361(24): 2342-52.

  15. Bordeaux JS, Martires KJ, Goldberg D et al. Prospective evaluation of dermatologic surgery complications including patients on multiple antiplatelet and anticoagulant medications. J Am Acad Dermatol 2011; 65: 576-83.

  16. Patel MR, Mahaffey KW, Garg J et al. rocket af Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10): 883-91.

  17. Eriksson BI, Borris LC, Friedman RJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358(26): 2765-75.

  18. Lassen MR, Ageno W, Borris LC et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358(26): 2776-86.

  19. Turpie AGG, Lassen MR, Davidson BL et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (record-4): a randomised trial. Lancet 2009; 373(9676): 1673-80.

  20. Lassen MR, Raskob GE, Gallus A et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361(6): 594-604.

  21. Lassen MR, Raskob GE, Gallus A et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (advance-2): a randomised double-blind trial. Lancet 2010; 375(9717): 807-15.

  22. Lassen MR, Gallus A, Raskob GE et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363(26): 2487-98.

  23. Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364(9): 806-17.

  24. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365(11): 981-92.

  25. Weisman S, Graham D. Evaluation of the benefits and risks of lowdose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002; 162: 2197-202.

  26. Bartlett GR. Does aspirin affect outcome of minor cutaneous surgery? Br J Plast Surg 2001; 54: 214-6.

  27. Lawrence C, Sakuntabhai A, Tiling-Grosse S. Effect of aspirin and nonsteroidal anti-inflammatory drug therapy on bleeding complications in dermatological surgery patients. J Am Acad Dermatol 1994; 31: 988-92.




2020     |     www.medigraphic.com